Diabetes Control & Complications Trial (DCCT)
Jump to navigation
Jump to search
Introduction
Demonstrates that the risks for development & progression of retinopathy, nephropathy & neuropathy with diabetes mellitus are:
- increasing levels of hemoglobin A1c
- reduced by 35-75% with intensive treatment targeted at near-normal glycemia
Methods
Adults & adolescents with type 1 diabetes mellitus
- intensive treatment group
- received at least 3 insulin injections/day
- checked blood glucose 4 times/day
- conventional treatment group (control)
- 1-2 insulin injections/day
- checked blood glucose daily
Ref 2c followed 175 of 195 adolescents for an additional 4 years. In this extended study nephropathy & retinopathy were diminished in the intensive treatment group; however, HgbA1c was not different.
Notes
- Epidemiology of Diabetes Interventions & Complications (EDIC) study is a long-term follow-up of DCCT.[4]
Results:
- intensive glycemic control can reduce risk for macrovascular complications in type 1 diabetes (after 17 years)
More general terms
References
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- ↑ Journal Watch 22(3):20, 2002 Diabetes Control & Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions & Complications (EDIC) Research Group a) N Engl J Med 329:977, 1993 b) J Pediatri 125:228, 1994 c) J Pediatr 139:804, 2001
- ↑ Diabetes Control and Complications Trial (DCCT) http://diabetes.niddk.nih.gov/dm/pubs/control/index.htm
- ↑ 4.0 4.1 Nathan DM et al, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med. 2005 Dec 22;353(25):2643-53. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16371630
Cefalu WT Glycemic control and cardiovascular disease - should we reasses clinical goals N Engl J Med. 2005 Dec 22;353(25):2707-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16371637